BUZZ — New mid — term targets lift Lonza shares

* Swiss contract drug manufacturer Lonza rises 2.2% after setting new mid-term targets and confirming its 2026 outlook * Lonza targets 10% to 13% organic sales growth and a core EBITDA margin in the high thirties in the medium term * Vontobel says the updated targets imply some upside to its estimates and sees free cash flow conversion improving * Zuercher Kantonalbank highlights that the new margin ambitions are significantly higher than the market had expected * Lonza shares are up around 8% this year, with 24 of 26 analysts rating it “buy” or “strong buy" ($1 = 0.8319 Swiss francs) (Reporting by Kira Britten) ((Kira.Britten@thomsonreuters.com)